SAM
ABMD

Silvercrest Asset Management’s Abiomed Inc ABMD Stock Holding History

Silvercrest Asset Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-700
Closed -$232K – 870
2022
Q1 		$232K Hold
700
– – ﹤0.01% 798
2021
Q4 		$251K Hold
700
– – ﹤0.01% 772
2021
Q3 		$228K Buy
+700
New +$237K ﹤0.01% 795

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Silvercrest Asset Management's ABMD Position: Q2 2022 in Review

Silvercrest Asset Management sold out of Abiomed Inc (ABMD) in Q2 2022, closing a stake of 700 shares — an estimated $232K sold.

Silvercrest Asset Management first reported a position in ABMD in Q3 2021 and held it in 3 quarters. The position peaked at $251K in Q4 2021. 496 funds tracked by Wall St. Rank hold ABMD as of Q2 2022.

  • Silvercrest Asset Management reported no remaining Abiomed Inc position as of Q2 2022 after selling out during the quarter.
  • Silvercrest Asset Management sold 700 Abiomed Inc shares in Q2 2022, an estimated $232K.
  • Silvercrest Asset Management first reported a position in Abiomed Inc in Q3 2021 and held it in 3 quarters.
  • Silvercrest Asset Management's Abiomed Inc position peaked at $251K in Q4 2021.
  • 496 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2022.

Based on Silvercrest Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.